Accessibility Menu
SOPHiA Genetics logo

SOPHiA Genetics(NASDAQ) SOPH

Current Price$6.45
Market Cap$531.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-62%
5 YearN/A
1 Year+70%
1 Month+16%
SOPHiA Genetics last closing stock price
MetricPriceDate
Last closeUSD 6.332026-07-20
SOPHiA Genetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.66%USD 5.722026-07-13
1 month+15.93%USD 5.462026-06-18
3 month+23.63%USD 5.122026-04-21
Year to date+35.55%USD 4.672025-12-31
1 year+70.16%USD 3.722025-07-18
3 year+49.29%USD 4.242023-07-21
Since inception-62.23%USD 16.762021-07-23

SOPHiA Genetics Financials at a Glance

Market Cap

$531.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$81.18M

Net Income (TTM)

-$80.94M

EPS (TTM)

-$1.18

P/E Ratio

-5.36

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.45

Volume

7,738

Open

$6.57

Previous Close

$6.33

Daily Range

$6.32 - $6.68

52-Week Range

$2.92 - $6.68

Estimated Earnings Date

Aug 4, 2026

SOPH News

No articles available.

SOPH: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SOPHiA Genetics

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe.

Products and Services
  • SOPHiA DDM platform for data analysis and insights
  • Cloud-native SaaS solutions for healthcare applications
  • Comprehensive support services for users and partners
Growth Outlook
  • Revenue of $21.7 million in Q4 2025, showing consistent growth
  • Strong gross profit margin of 68% in Q1 2026
  • Increasing adoption of the SOPHiA DDM platform across global markets
Financial Highlights
  • Net income of -$19.3 million in Q1 2026, reflecting ongoing investment in R&D
  • Cash and cash equivalents of $65.4 million as of March 2026
  • Current ratio of 2.06, indicating strong short-term financial health
SOPHiA GENETICS S.A. has established itself as a leader in the healthcare technology sector, particularly with its innovative SOPHiA DDM platform. The company has demonstrated a commitment to growth, as evidenced by its increasing revenue and strong gross profit margins. Despite facing challenges reflected in its net income, the company maintains a solid cash position, which supports ongoing investments in research and development. The current ratio indicates a robust ability to meet short-term obligations, positioning the company favorably for future opportunities in the expanding healthcare market.
AI Generated • Jun 24, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

415

CEO

Jurgi Camblong, PhD, EMBA

Website

www.sophiagenetics.com

Headquarters

Rolle, VD 1025, CH

SOPH Financials

Key Financial Metrics (TTM)

Gross Margin

67.28%

Operating Margin

-88.39%

Net Income Margin

-99.70%

Return on Equity

-140.63%

Return on Capital

-64.38%

Return on Assets

-51.55%

Earnings Yield

-18.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$531.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

83.90M

Volume

7.74K

Avg. Volume

214.91K

Financials (TTM)

Gross Profit

$54.62M

Operating Income

-$71.75M

EBITDA

-$66.08M

Operating Cash Flow

-$42.12M

Capital Expenditure

-$3.31M

Free Cash Flow

-$45.43M

Cash & ST Invst.

$65.39M

Total Debt

$62.43M

SOPHiA Genetics Performance Analysis

SOPHiA Genetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 47,560,00017.6%
20232023-12-31USD 62,371,00031.1%
20242024-12-31USD 65,173,0004.5%
20252025-12-31USD 77,271,00018.6%
SOPHiA Genetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-303.1%
Q32025-09-306.2%
Q42025-12-3111.5%
Q12026-03-31-0.1%
SOPHiA Genetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3618.3%
20232023-12-31USD -1.22-10.6%
20242024-12-31USD -0.95-22.4%
20252025-12-31USD -1.1723.6%
SOPHiA Genetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-26.9%
Q32025-09-309.1%
Q42025-12-316.7%
Q12026-03-313.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$21.69M

+22.0%

Gross Profit

$14.75M

+20.8%

Gross Margin

68.01%

N/A

Market Cap

$531.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.28M

N/A

Employees

415

N/A

Net Income

-$19.32M

-11.1%

EBITDA

-$14.65M

-5.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$65.39M

-4.6%

Total Debt

$62.43M

+107.2%

Accounts Receivable

$14.31M

+33.8%

Inventory

$7.09M

+40.3%

Long Term Debt

$59.71M

+114.5%

Short Term Debt

$2.71M

+18.6%

Return on Assets

-51.55%

N/A

Return on Invested Capital

-64.99%

N/A

Free Cash Flow

-$17.06M

-39.3%

Operating Cash Flow

-$16.18M

-50.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRCNRC Health
$21.00-1.94%
SLPSimulations Plus, Inc.
$18.22+0.05%
LRMRLarimar Therapeutics, Inc.
$3.88+1.17%
CLLSCellectis S.A.
$2.73+5.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$6.71+2.88%
NOKNokia
$10.71+0.06%
UTZUtz Brands
$14.11+0.89%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.41+0.06%

Questions About SOPH

What is the current price of SOPHiA Genetics?

SOPHiA Genetics is trading at $6.45 per share.

What is the 52-week range for SOPHiA Genetics?

Over the past 52 weeks, SOPHiA Genetics has traded between $2.92 and $6.68.

How much debt does SOPHiA Genetics have?

As of the most recent reporting period, SOPHiA Genetics reported total debt of $62.43M.

How much cash does SOPHiA Genetics have on hand?

SOPHiA Genetics reported $65.39M in cash and cash equivalents in its most recent financial results.

What is SOPHiA Genetics’s dividend yield?

SOPHiA Genetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services